{"id":"paclitaxel-bevacizumab-liposomal-doxorubicin-capecitabine","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"20-40","effect":"Mucositis"},{"rate":"20-40","effect":"Diarrhea"},{"rate":"15-30","effect":"Hand-foot syndrome"},{"rate":"15-25","effect":"Hypertension"},{"rate":"5-15","effect":"Cardiotoxicity"},{"rate":"5-10","effect":"Bleeding/thrombotic events"}]},"_chembl":null,"_fixedAt":"2026-03-30T11:59:42.103376","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paclitaxel stabilizes microtubules to prevent cell division. Bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis and vascular supply. Liposomal doxorubicin intercalates DNA to cause strand breaks and cell death. Capecitabine is a prodrug converted to 5-FU, which inhibits thymidylate synthase and disrupts nucleotide synthesis. Together, these agents provide synergistic cytotoxic and anti-angiogenic effects.","oneSentence":"This combination regimen uses multiple chemotherapy agents and an anti-angiogenic antibody to kill cancer cells through distinct mechanisms: microtubule stabilization, vascular disruption, DNA intercalation, and antimetabolite activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:26.271Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer (likely indication given Borstkanker Onderzoek Groep focus on breast cancer)"}]},"_fixedFields":["pubmed(5)"],"trialDetails":[{"nctId":"NCT05985655","phase":"PHASE1, PHASE2","title":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.","startDate":"2023-07-06","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)","enrollment":230},{"nctId":"NCT03563144","phase":"PHASE2","title":"QUILT-3.088: NANT Pancreatic Cancer Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Metastatic Pancreatic Cancer","enrollment":""},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT01935492","phase":"PHASE3","title":"8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Borstkanker Onderzoek Groep","startDate":"2010-11","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer","enrollment":420},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT00262067","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)","status":"UNKNOWN","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Metastatic Breast Cancer","enrollment":1237}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"recentPublications":[{"date":"2024 Jun 14","pmid":"39013199","title":"Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.","journal":"Revista colombiana de obstetricia y ginecologia"},{"date":"2020 Jun","pmid":"32141389","title":"Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.","journal":"Acta oncologica (Stockholm, Sweden)"},{"date":"2009 Aug","pmid":"19808124","title":"Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.","journal":"Clinical therapeutics"},{"date":"2008 Nov","pmid":"18991787","title":"Chemotherapy and targeted agents for elderly women with advanced breast cancer.","journal":"Recent patents on anti-cancer drug discovery"},{"date":"2005 Jun","pmid":"16082422","title":"Gateways to clinical trials.","journal":"Methods and findings in experimental and clinical pharmacology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Non-pegylated liposomal doxorubicin (Myocet®)","Non-pegylated liposomal doxorubicin (Myocet®):"],"phase":"phase_3","status":"active","brandName":"Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine","genericName":"Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine","companyName":"Borstkanker Onderzoek Groep","companyId":"borstkanker-onderzoek-groep","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses multiple chemotherapy agents and an anti-angiogenic antibody to kill cancer cells through distinct mechanisms: microtubule stabilization, vascular disruption, DNA intercalation, and antimetabolite activity. Used for Metastatic breast cancer (likely indication given Borstkanker Onderzoek Groep focus on breast cancer).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}